Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib. METHODS: We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR). RESULTS: Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR. CONCLUSION: These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance. TRIAL REGISTRATION: ClinicalTrials.gov NCT00990808. FUNDING: Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Self-citationSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Self-citationKosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain
Lütjohann, D., Brzezinka, A., Barth, E., Abramowski, D., Staufenbiel, M., von Bergmann, K., Beyreuther, K., Multhaup, G., & Bayer, T. A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200071-jlr200 · Cited by 158
A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Yamamoto, T., Lu, C., & Ryan, R. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199042 · Cited by 96
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“178,179 While anacetrapib treatment led to a small risk reduction, putatively linked to a decrease in LDL-C, greater LDL-C reduction with evace-trapib did not confer cardiovascular benefit.”
BackgroundSelf-citationTrials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 305
Self-citationPCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“Anacetrapib treatment also increases the LDL TG/cholesterol ratio and LDL size and increases LDL-apoB-100 clearance (93).”
BackgroundThomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96
Self-citationLipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23
Metadata
- Authors
- Millar, J. S., Reyes-Soffer, G., Jumes, P., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L., Tohyama, J., Johnson-Levonas, A. O., Wagner, J. A., Holleran, S., Obunike, J., Liu, Y., Ramakrishnan, R., Lassman, M. E., Gutstein, D. E., Ginsberg, H. N., & Rader, D. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-05-11
- Volume
- 125
- Issue
- 6
- Pages
- 2510-2522
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1488193441
- Cited by
- 89
- References
- 10
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.